Iovance Biotherapeutics
IOVA
82 hedge funds and large institutions have $273M invested in Iovance Biotherapeutics in 2015 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 29 increasing their positions, 23 reducing their positions, and 14 closing their positions.
2,871% more call options, than puts
Call options by funds: $6.39M | Put options by funds: $215K
37% more capital invested
Capital invested by funds: $199M → $273M (+$74.1M)
26% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 23
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
3% more funds holding
Funds holding: 80 → 82 (+2)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.2M |
| 2 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.16M |
| 3 |
RIM
RS Investment Management
San Francisco,
California
|
+$2.13M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$1.93M |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
+$639K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$2.46M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
-$2.03M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$1.73M |
| 4 |
Wells Fargo
San Francisco,
California
|
-$1.26M |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$750K |
IOVA Hedge Fund Activity: Q4 2015 in Review
82 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2015, worth a combined $273M — up 37% from $199M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new IOVA positions and 14 closed out — a net gain of 2 holders — while 29 added to existing stakes and 23 trimmed.
The largest buyer was BlackRock Fund Advisors, adding an estimated $4.2M. The largest seller was Citigroup, cutting an estimated $2.46M.
- 82 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2015, up from 80 in Q3 2015.
- Funds reported $273M of Iovance Biotherapeutics stock for Q4 2015, up 37% quarter-over-quarter.
- 16 funds opened new Iovance Biotherapeutics positions in Q4 2015 and 14 closed out, a net change of +2 holders.
- The largest Iovance Biotherapeutics buyer in Q4 2015 was BlackRock Fund Advisors, an estimated $4.2M added.
- The largest Iovance Biotherapeutics seller in Q4 2015 was Citigroup, an estimated $2.46M sold.
Based on aggregated 13F filings for Q4 2015.